Breakdown of the epithelial barrier because of toxins or other insults leads to severe colitis. Interleukin-10 (IL-10) is a critical regulator of this, yet its cellular targets and mechanisms of action are not resolved. We address this here. Mice with a macrophage-selective deletion of IL-10Ra (IL-10Ra
INTRODUCTION
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are characterized by mucosal damage and ulceration. Breech of the intestinal epithelial barrier by commensal bacteria triggers the inflammation that is responsible for IBD pathogenesis. Dextran sodium sulfate (DSS) administration has commonly been used to model ulcerative colitis. Ingested DSS concentrates in the colon where it disrupts the epithelial barrier and induces a secondary inflammatory response characterized by the production of proinflammatory cytokines, including interleukin (IL)-1b, IL-6, IL-12, IL-18, and tumor necrosis factor-a (TNF-a). [1] [2] [3] [4] [5] [6] IL-10 is a predominantly anti-inflammatory cytokine with an essential role in maintaining gastrointestinal homeostasis. Genetic variants in IL-10 or the IL-10 receptor (IL-10R) are associated with IBD susceptibility. Older IL-10 À / À mice develop spontaneous colitis, and IL-10 deficiency exacerbates colitis in several models, including DSS and T-cell transfer colitis. [7] [8] [9] [10] [11] Moreover, pharmacologically administered IL-10 ameliorates colitis in mice by inhibiting intestinal inflammation and suppressing proinflammatory cytokine production. [12] [13] [14] IL-10 is produced by hematopoietically derived cells, including T cells, B cells, dendritic cells (DCs), and macrophages. Signaling through the IL-10R downmodulates TNF-a production and proinflammatory signaling through various mechanisms, including the induction of SOCS3, other antiinflammatory proteins, and miRNA. [15] [16] [17] The cell types responsible for the anti-inflammatory effects of IL-10 and mucosal protection in colitis have not been resolved. The IL-10R is a heterodimer comprising an IL-10Ra chain that is specific for IL-10 and an IL-10Rb that is shared with other IL-10-family cytokines, including IL-22, IL-26, and the interferon-l family. Whereas IL-10Rb is largely restricted to hematopoietic cells, IL-10Ra is broadly expressed. We recently described the production of mice allowing the conditional deletion of IL-10Ra that we apply here to assess how lineagespecific IL-10 responsiveness influences colitis severity. 18 We identify a selective role for macrophage IL-10Ra, and find suppression of nitric oxide (NO) and reactive oxygen species (ROS) production to be critical downstream mechanisms.
RESULTS

Macrophage IL-10 response limits the severity of DSS-induced colitis
To define the cellular lineages responsible for the protective effect of IL-10 in colitis, we first generated mixed chimeras in which bone marrow from mice with a germline deletion of IL-10Ra (CMV-Cre Â IL-10Ra fl/fl ; IL-10Ra À / À ) or wild-type (WT) controls was transplanted in a crisscross manner into lethally irradiated IL-10Ra À / À or IL-10Ra WT recipients. Colitis was induced by oral administration of 3% DSS for 5 days. No effect of IL-10Ra deficiency restricted to radioresistant host populations was seen (Supplementary Figure S1 online). In contrast, mice with IL-10Ra deficiency in the bone marrow grafts developed significantly worse disease compared with those receiving WT bone marrow. This implies that radiosensitive hematopoietic populations are primarily responsible for IL-10's effects.
To further dissect the lineages responsible, we bred C57BL/ 6-IL-10Ra
fl/fl mice with mice expressing Cre transgenes in macrophages (Lys-Cre; IL-10Ra Mdel ), T cells (CD4-Cre; IL-10Ra After colitis induction, control IL-10Ra fl/fl mice typically lost B15-20% of body weight by days 7 to 8, with subsequent restoration of initial weight (Figure 1a-d) . IL-10Ra  DCdel ,  IL-10Ra   Bdel   , and IL-10Ra Tdel mice displayed identical disease kinetics and magnitude, indicating that T-cell, B-cell, and DC responsiveness to IL-10 did not affect clinical severity (Figure 1a-c) . In contrast, IL-10Ra
Mdel mice developed more severe disease (Figure 1d ). Mean maximal weight loss was greater than for controls (25 ± 5 vs. 16 ± 4%) and 2/10 IL-10Ra
Mdel mice but no controls had to be culled because of their illness. At a higher dose of 4% DSS, 6/10 (60%) IL-10Ra
Mdel mice, although no control mice, died or required killing (Figure 1e) .
The Lys-Cre transgene is expressed in granulocytic cells in addition to macrophages. 19 Comparison of DSS-treated IL-10Ra fl/fl and IL-10Ra Mdel mice indicated that the IL-10R deficiency did not lead to differences in the percent or absolute numbers of granulocytes in the lamina propria (LP; Supplementary Figure S3 ). To more definitively exclude a role for these cells in the enhanced disease in IL-10Ra
Mdel mice, we depleted them with anti-Ly6G antibody (Ab) before DSS administration. 20 Neutrophils remained undetectable for 49 days (data not shown). Despite this, the anti-Ly-6G Ab treatment did not significantly alter disease course or severity in either IL-10Ra fl/fl or IL-10Ra
Mdel mice (Figure 1f ; P40.05). This indicates that macrophage and not granulocytes are responsible for the protective effects of IL-10 in colitis.
To better delineate the contribution of macrophage, we compared disease in IL-10Ra
Mdel , IL-10 À / À , and IL-10Ra
mice. The latter two lines have global deficiency of IL-10 or its specific receptor. All three lines developed more severe disease than IL-10Ra fl/fl controls ( Figure 1g ). However, disease in IL-10Ra
Mdel mice did not significantly differ at any time point from that in IL-10Ra À / À or IL-10 À / À mice. Therefore, colitis in IL-10Ra
Mdel mice is comparable to that in mice ubiquitously deficient in the IL-10 response. Cumulatively, these results implicate the macrophage lineage as the primary mediator of IL-10 effects in colitis induced by barrier disruption.
Increased immunopathology in IL-10Ra
Mdel colonic mucosa
We anticipated that the enhanced disease in IL-10Ra
Mdel mice would be associated with increased mucosal damage and hence gastrointestinal blood loss. Indeed, significantly increased bleeding was seen in IL-10Ra
Mdel compared with IL-10Ra fl/fl cohorts on each day that blood was detectable (Figure 2a) . This was correlated with histologic changes. IL-10Ra
Mdel colons, isolated at day 7, showed a more extensive cellular infiltrate, increased submucosal edema, and increased epithelial erosion compared with IL-10Ra fl/fl controls ( Figure 2b) . Observer-blinded scoring demonstrated a significantly greater area of tissue destruction and severity of inflammation, ulceration, and hyperplasia in the IL-10Ra
Mdel colons. Total histologic score was 2.7±2.3 and 7.6±1.8 (scale 0-12) for IL-10Ra fl/fl and IL-10Ra Mdel mice, respectively ( Figure 2c ).
Consistently, IL-10Ra
Mdel colons were shorter than controls (5.8 ± 0.6 vs. 7.2 ± 0.8 cm, Figure 2d ,e). Therefore, by clinical, gross pathologic, and histopathologic measures, IL-10Ra Mdel mice develop colitis that is increased in severity.
Importantly, we did not observe clinical evidence of spontaneous colitis in our IL-10Ra
Mdel colony, which was housed under Helicobacter spp.-free conditions, arguing against the development of subclinical disease before DSS administration. We verified this histologically. Colon tissue sections from unmanipulated IL-10Ra fl/fl and IL-10Ra Mdel mice were equivalent, and abnormalities indicating incipient colitis were not observed (data not shown).
Unimpaired epithelial regeneration in IL-10Ra
Mdel mice
To assess for alterations in barrier integrity with loss of macrophage IL-10 responsiveness, we administered fluorescein isothiocyanate (FITC)-dextran by gastric lavage and measured its passage into the blood stream. Levels of FITC-dextran were greater in IL-10Ra Mdel than IL-10Ra fl/fl blood (Supplementary Figure S4a) , consistent with increased barrier disruption.
Impaired epithelial regeneration from crypt progenitors has been associated with enhanced colitic inflammation, 21 and may have contributed to the barrier disruption. We analyzed this by pulsing unmanipulated or colitic IL-10Ra
Mdel or IL-10Ra
fl/fl mice with 5-bromodeoxyuridine for 2 h, and then measuring its incorporation into the colonic epithelium. No significant difference was detected between IL-10Ra Mdel and IL-10Ra fl/fl colons, either in untreated mice or mice receiving DSS (Supplementary Figure S4b) , indicating that differential epithelial turnover is not responsible for the different disease susceptibilities. 
Macrophage infiltrate in DSS colitis
As an alternative explanation for the enhanced IL-10Ra Mdel colitis, we looked for changes in the number and maturation state of IL-10Ra
Mdel lamina propria macrophages (LPMfs). Surprisingly, gated colonic CD11b
LPMfs, a population we also characterized as CD45
þ and SiglecF À , were not significantly increased in colitic IL-10Ra
Mdel compared with IL-10Ra fl/fl mice ( Figure 3a and Supplementary Figure S5) .
LPMfs are functionally diverse. Takada et al. 22 separated CD11b þ F4/80 þ CD11c -LPMfs into a SSC hi population, referred to as LPMf1, and a SSC lo population, LPMf2, with distinct cytokine production and chemokine response properties. LPMf subsets expressing CD11c have been more recently identified during intestinal inflammation. 23 We assessed LPMfs, gated to include CD11c À and CD11c dim cells, in IL-10Ra
Mdel and IL-10Ra fl/fl mice with colitis. These did segregate into discrete SSC hi and SSC lo populations ( Figure 3b ). However, the proportions of SSC hi and SSC lo cells did not significantly differ ( Figure 3c ). Furthermore, markers associated with LPMf activation and subset assignment, including CD40, CD80, CD86, and Toll-like receptor 2, were comparably expressed in IL-10Ra
Mdel and IL-10Ra fl/fl LPMfs (Supplementary Figure S6) . Therefore, despite the difference in disease severity, IL-10Ra
Mdel and IL-10Ra fl/fl LPMfs are phenotypically similar and present in similar numbers.
IL-10Ra
Mdel macrophages actively promote colitis and do not outcompete WT cells
To gain insight into whether IL-10Ra
Mdel macrophages play a dominant role in increasing colitis severity, we generated hematopoietic chimeras in which lethally irradiated WT recipients received stem cell rescue with WT, IL-10Ra Mdel , or a mixture of WT and IL-10Ra
Mdel bone marrow. Cell origins were distinguishable by the alternative expression of CD45.1 and CD45.2, allowing us to compare the populations in a competitive manner. As anticipated, recipients of IL-10Ra
Mdel marrow developed more severe colitis than those receiving WT marrow. However, mice receiving a mixture of WT and IL-10Ra Mdel marrow developed disease essentially identical to those receiving IL-10Ra
Mdel marrow alone (Supplementary Figure S7 ) despite equivalent proportions of IL-10Ra
Mdel and IL-10Ra fl/fl cells among transferred bone marrow cells, blood macrophage before colitis induction, and macrophage in the LP, spleen, and blood in diseased mice (data not shown). Implicitly, altered macrophage function rather than competitiveness acts to worsen disease in IL-10Ra
Mdel mice.
Increased proinflammatory cytokine production in IL-10Ra Mdel colons
To functionally analyze the impact of the IL-10Ra
Mdel mutation, we next measured levels of IL-1b, IL-18, IL-6, monocyte chemotactic protein-1, and TNF-a, proinflammatory cytokines associated with colitis, in whole colons from day 7 colitic mice. Each was increased in IL-10Ra Mdel compared with IL-10Ra fl/fl controls ( Figure 4a , Po0.05). IL-10 is also produced by activated macrophages, initiating an autocrineand paracrine-negative feedback loop. However, IL-10 levels were unaffected, indicating that the inability of macrophages to respond to IL-10 did not influence its overall quantity.
We further characterized specific cytokine production by macrophages themselves. Cytokine transcription was measured in neutrophil-depleted flow-sorted CD11b þ F4/80 þ CD11c À /dim Ly6G À /lo LPMfs. A 4.4 ± 0.6-, 2.8 ± 0.4-, and 1.5 ± 0.2-fold increase in IL-1b, TNF-a, and IL-12p35 message, respectively, was seen in IL-10Ra
Mdel compared with IL-10Ra fl/fl LPMfs ( Figure 4b ). In contrast, transforming growth factor-b message was decreased in IL-10Ra Mdel LPMfs by 0.42±0.08-fold, whereas IL-6, IL-10, and IL-23p19 mRNA were essentially unchanged. Therefore, loss of macrophage responsiveness to IL-10 leads to an overall shift toward increased proinflammatory cytokine production.
The role of T helper type 17 cells in DSS colitis is unclear, with one study indicating positive and negatives roles for IL-17F and IL-17A, respectively, and another identifying disease-promoting effects of IL-17A. 4 , 24 We did not observe differences in IL-17A levels in whole colons or in the numbers of IL-17A-or IL-17F-positive infiltrating T lymphocytes during DSS colitis when comparing IL-10Ra
Mdel and IL-10Ra fl/fl mice (data not shown). Considering this and the similar IL-23 mRNA expression in IL10Ra
Mdel and IL-10Ra fl/fl LPMfs, modulation of Th17 cells does not appear to play a role in the differential disease.
TNF-a is among the earliest macrophage biomarkers produced in DSS colitis. It promotes secondary secretion of other proinflammatory cytokines, and is potently downmodulated by IL-10. 25 These features, together with the increased Mdel and IL-10Ra fl/fl mice on day 7 after colitis induction. Absolute numbers of production of TNF-a in IL-10Ra
Mdel colons, potentially implicate it in the exacerbated disease. To test this, we blocked its activity using anti-TNF-a Ab. Treatment reduced disease severity in both IL-10Ra fl/fl and IL-10Ra Mdel mice (Supplementary Figure S8) . However, the extent of this was similar in each line, and treated IL-10Ra
Mdel mice still developed more severe disease than even untreated IL-10Ra fl/fl controls (Po0.01). Therefore, increased TNF-a production may play a role but is inadequate in itself to explain the heightened IL-10Ra
Mdel disease.
NO modulation of IL-10Ra
Mdel colitis IL-10 potently inhibits inducible nitric oxide synthase (iNOS), and thereby NO production. The integrated effects of NO antimicrobial activity, toxic actions on the barrier, and cell signaling activity may alternatively promote or diminish colitis. In DSS colitis, excessive NO production worsens disease, although protective effects of NO have also been identified. 26 To assess iNOS activity, we sorted LPMfs from colitic mice and quantified iNOS mRNA. Levels were 4.7±0.8-fold higher in IL-10Ra Mdel compared with IL-10Ra fl/fl macrophages. Arginase, which inhibits iNOS by degrading NO's nitrogen source, was reciprocally, although less strongly, decreased (0.52 ± 0.07-fold, Figure 5a) .
We also analyzed the accumulation of iNOS in homogenized LP cells from colitic mice using an assay for iNOS functional activity. This indicated a 42-fold increased activity in IL-10Ra
Mdel than IL-10Ra fl/fl colons (Figure 5b , 10.8±3.3 vs. 5.2±2.2 mmol nitrite produced per mg protein).
To assess the impact of this NO, cohorts of IL-10Ra Mdel or IL-10Ra fl/fl mice were treated with aminoguanidine hydrochloride (AG), a selective iNOS inhibitor. Consistent with the mixed roles of NO in DSS colitis, treatment of IL-10Ra fl/fl mice led to only a mild and nonsignificant trend toward reduced disease severity (Figure 5c ). In contrast, a more substantial protective effect was apparent in IL-10Ra
Mdel mice. Mean weight loss at disease peak in AG-treated IL-10Ra Mdel mice was 15 ± 3% vs. 24 ± 4% for untreated mice (Po0.05). A similar pattern was observed when comparing bleeding scores and colon lengths for the different treatments (Figure 5d and Supplementary Figure S9 ). There was a nonsignificant trend toward diminished bleeding in AG-treated vs. untreated IL-10Ra fl/fl mice; however, this proved significant and more substantial in IL-10Ra
Mdel mice. As an alternative approach to address the role of NO production, we selectively inhibited arginase with S-(2-boronoethyl)-l-cysteine (BEC). BEC increased peak weight loss in IL-10Ra fl/fl mice (17±3% treated vs. 12±2% untreated, Po0.05, Figure 5e ). Furthermore, bleeding scores in IL-10Ra fl/fl mice were significantly greater in the mice receiving BEC (Figure 5f , Po0.05) than untreated controls. Therefore, arginase inhibition promotes disease in WT mice. In contrast, BEC did not significantly affect weight loss or bleeding score in IL-10Ra
Mdel mice, although a nonsignificant trend toward increased bleeding was apparent. Colon length measurements showed similar trends (Supplementary Figure S9 online). Therefore, arginase inhibition, which will increase NO production, preferentially promotes colitis in IL-10Ra fl/fl mice. In IL-10Ra Mdel mice, where NO production is already elevated and arginase diminished, an effect of further reduction in arginase activity is not detected. Cumulatively, these results indicate a role for elevated NO production in the aggravated colitis in IL-10Ra
Increased reactive oxygen generation in IL-10Ra Mdel colitis ROS production is regulated by IL-10 and is implicated in colitis. Analysis of p47phox À / À mice demonstrated no difference from controls in DSS colitis severity. Nevertheless, as for NO, the role of ROS in colitis is multifaceted. ROS is important in mediating protection against bacteria entering the mucosa. 27 At the same time, excess production may be damaging. Indeed, ROS production defects or antioxidant treatments can potentiate disease protection in some circumstances. We measured ROS production in LPMfs by staining with CM-H2DCFDA. ROS was undetectable in LPMfs from untreated mice (not shown). LPMfs from IL-10Ra fl/fl mice with colitis stained positively for ROS (Figure 6a) . However, IL-10Ra
26,28
Mdel LPMfs displayed a significant increase in this (IL-10Ra fl/fl MFI ¼ 42.9 ± 14.1, IL-10Ra Mdel MFI ¼ 134.0 ± 24.4, Po0.01). This increase in ROS was specific for macrophages; LP-derived DCs, B cells, and T cells did not show this difference. Some splenic macrophages showed detectable ROS production; however, quantities were substantially decreased compared with the LP and did not differ between IL-10Ra
Mdel and IL-10Ra fl/fl mice. Therefore, ROS production is markedly and selectively elevated in IL-10Ra
Mdel LPMfs. To clarify the role of the increased IL-10Ra
Mdel ROS, we treated the mice with an ROS scavenger, N-acetyl-L-cysteine (NAC). NAC did not affect the weight loss or colon length in IL-10Ra fl/fl mice ( Figure 6b ,c and Supplementary Figure S9) . Comparison of treated and untreated mice did show a trend toward a decrease in bleeding scores, but this was not significant (Figure 6f) . The limited effect of NAC in WT mice was not unexpected considering the similar previously documented results with p47phox deficiency. However, in IL-10Ra Mdel mice, where ROS production is elevated, NAC led to a more substantial attenuation of disease. Maximal weight loss was decreased from 27 ± 2 to 21 ± 2% (Figure 6b,d, Po0.05) . A trend toward decreased bleeding score was seen but, similar to IL-10Ra fl/fl mice, was not significant (Figure 6f ). Therefore, antioxidant treatment shows greater effectiveness in IL-10Ra
Mdel than IL-10Ra fl/fl mice. NAC may also protect against ROS, such as peroxynitrites, formed by the reaction of ROS and NO. Therefore, part of its activity may be secondary to its effects on NO-derived species. To determine if NAC actions were still discernible after inhibiting iNOS, we treated mice with both AG and NAC (Figure 6b-e) . These demonstrated complementary effects. Dually treated control IL-10Ra fl/fl mice showed a limited improvement over untreated or NAC-only treated mice (Figure 6b,c) . Their bleeding scores were not significantly improved compared with mice treated with NAC alone but were compared with untreated animals (Figure 6f) . In contrast, IL-10Ra
Mdel mice treated with both inhibitors showed markedly diminished weight loss, with a significant effect compared with NAC treatment by itself (Figure 6b,d,e) . Peak weight loss of treated IL-10Ra
Mdel mice did not significantly differ from that of untreated IL-10Ra fl/fl controls and was only mildly more severe than similarly treated IL-10Ra fl/fl mice. The bleeding scores of treated IL-10Ra
Mdel mice did not significantly differ from untreated IL-10Ra fl/fl mice, although they did remain elevated compared with NAC or NAC-and AG-treated IL-10Ra fl/fl controls ( Figure 6f) . Therefore, dual inhibition of the ROS and iNOS pathways substantially alleviates the enhanced disease in IL-10Ra Mdel mice, whereas it more modestly affects disease in IL-10Ra fl/fl controls.
DISCUSSION
Intestinal immune inflammatory and regulatory pathways exist in a highly dynamic balance, ensuring that inevitable disruptions in the mucosal barrier are repaired without undo inflammation or the development of a self-perpetuating colitic process. IL-10 plays a critical role in this and governs IBD susceptibility. Macrophages may serve as a specific control point. MyD88 deletion in macrophages or DCs but not intestinal epithelial cells affects spontaneous colitis in IL-10 À / À mice. 29 Macrophagespecific deletion of signal transducer and activator of transcription 3, which signals downstream of multiple cytokines including IL-10, 30 leads to chronic IBD. However, the cell types directly responsible for the protective effects of IL-10 in colitis have not been definitively resolved.
We did not identify a role for nonhematopoietic IL-10Ra expression in IL-10-mediated colitis protection. Similarly, IL-10Ra Tdel , IL-10Ra Bdel , and IL-10Ra
DCdel mice developed DSS colitis with a kinetics and severity identical to WT controls. In contrast, IL-10Ra
Mdel mice manifested more severe disease with increased mortality. This was comparable to that of mice wholly deficient in IL-10 or IL-10Ra. Granulocyte depletion further implicated macrophages as the primary cellular target for IL-10 after mucosal breech with DSS. Histopathologic changes in IL-10Ra Mdel mice were consistent with an increase in disease magnitude compared with WT controls, but not an altered disease quality.
The absence of a T-specific IL-10 effect is notable considering the documented effect of IL-10 in regulatory T-cell maintenance and disease severity in colitis induced by T-cell transfer into Rag À / À mice. 31 Similarly, T-cell response to IL-10 has been implicated in the immunoregulation of intestinal inflammation after aCD3 treatment. 32 Contrasting with these models, T cells appear to have a limited involvement in DSS colitis, reflecting the acute toxic influence of DSS on the colonic barrier and subsequent innate inflammatory response. Although changes in the T-cell compartment are evident after DSS treatment, this lineage is not essential for the colitis that may be comparably induced in Rag À / À mice and immunoreplete mice. 33, 34 It is also notable that IL-10Ra DCdel mice did not develop exacerbated DSS colitis. Figure S5 online) . Furthermore, sorted CD11c À and CD11c dim LPMfs from IL-10Ra
immunophenotype (Supplementary
Mdel mice both showed elevated levels of iNOS, TNFa, and IL-1b relative to controls (data not shown). This suggests that both CD11c À and CD11c dim populations contribute to the increased IL-10Ra
Mdel disease severity. The time course for disease in DSS colitis is highly abbreviated. One possible explanation for the lack of a CD11c-Cre effect is that as monocytes enter the colon, mature into LPMf, and some upregulate CD11c, there is insufficient time to induce Cre and delete the IL-10Ra gene, and for pre-existing expressed IL-10Ra protein to be depleted. Further comparisons of the IL-10Ra DCdel and IL-10Ra
Mdel mice are, however, warranted to clarify the mechanism(s) underlying the distinct effects of these different Cre transgenes.
LPMfs are activated in all commonly studied colitis models, 31, 35, 36 and we further assessed how their inability to respond to IL-10 is linked to exacerbated colitis. DSS disrupts the mucosal barrier. Defective epithelial regeneration may aggravate colitis, 21 although it was not observed here. IL-10 suppresses macrophage proinflammatory cytokine production, and colitic IL-10Ra
Mdel LPMfs produced more IL-1b and TNF-a than controls, although IL-10 itself was unaltered. The T-cell response is not essential to DSS colitis, 34 and in pilot studies we found no differences in interferon-g, IL-17, and IL-23 production by quantitative real-time reversetranscriptase-PCR (data not shown). Although proinflammatory cytokines are broadly elevated in IL-10Ra
Mdel colitis, we focused on TNF-a because of its direct cytopathic effects and prominent regulation by IL-10 in macrophage. TNF-a inhibition proved protective in both IL-10Ra
Mdel mice and controls, but to a similar extent, and disease in treated IL-10Ra
Mdel mice remained more severe than in even untreated IL-10Ra fl/fl controls. Therefore, although TNF-a plays a role in colitis development, it cannot in itself explain the increased IL-10Ra
Mdel disease susceptibility. We did not observe differences in macrophage numbers, phenotype, or segregation into SSC hi and SSC lo LPMf1 and LPMf2 populations. Similarly, mixed chimeras demonstrated that IL-10Ra
Mdel macrophages do not outcompete WT macrophages during colitis development, indicating that IL-10 is not affecting cellular localization, migration, or expansion. However, IL-10Ra
Mdel macrophages showed markedly elevated NO and ROS production that are important for clearing bacteria that traverse the disrupted mucosal barrier, 37, 38 although in excess they may also mediate direct tissue damage. 26, 28, [39] [40] [41] Importantly, inhibition of either NO or ROS led to no or modest effects on colitis severity in WT (IL-10Ra fl/fl ) mice. This is consistent with the mixed protective and pathologic functions of these agents. In contrast, colitis was more substantially alleviated by their inhibition in IL-10Ra Mdel mice. Indeed, weight loss in NAC/AG-treated IL-10Ra
Mdel was only mildly increased compared with similarly treated WT controls, indicating that inhibition of these pathways converts the more extreme disease in IL-10Ra
Mdel mice to one similar to that of WT mice. Limited studies have been performed in DSS colitis to identify immunopathologic mechanisms of ROS and NO, and it will be important in the future to further clarify how IL-10 influences the effects of these molecules. Nevertheless, our results are consistent with a model in which intestinal IL-10 acts to downregulate macrophage NO and ROS production after barrier insult. In the absence of adequate IL-10 signaling, damage produced by these mediators amplifies the toxic insult from DSS treatment and aggravates disease. The limited effect of NO and ROS inhibition in WT mice implies that IL-10 normally reduces these compounds to a level where their direct toxic actions are roughly balanced by their protective functions.
In summary, we demonstrate an indispensable and dominant role for macrophage IL-10 responsiveness in the protective effects of IL-10 in colitis development. We further demonstrate that IL-10 does not alter the competitive fitness of macrophages themselves, but rather impairs their effector functions, and most particularly their excessive production of pathologic reactive oxygen and nitrogen species.
fl/fl mice were generated on a C57BL/6 background as described previously 18 and bred with B6.129P2-Lyzs , Sigma) was administered intraperitoneally. Neutrophils were depleted using anti-Ly6G monoclonal Ab 1A8 (Bio X Cell, West Lebanon, NH). A total of 1 mg Ab per mouse was administered intraperitoneally 1 day before DSS treatment. Depletion was confirmed by flow cytometry. Body weight and gross blood were analyzed on a daily basis. 42 Bleeding scores were: 0, hemoccult negative (Beckman Coulter, Brea, CA); 1, hemoccult positive; 2, blood traces in stool; and 3, gross rectal bleeding.
Histology. Colons (day 7) were stained with hematoxylin and eosin. Three independent sections were assessed per mouse by a blinded reviewer. Inflammation scoring was as follows: 0, no or occasional inflammatory cells in the LP; 1, increased LP inflammatory cells; 2, confluence of inflammatory cells extending into the submucosa; and 3, transmural infiltrate extension of the infiltrate. Ulceration scoring was as follows: 0, no ulceration; 1, mild (1-2 ulcers per 40 crypts analyzed); 2, moderate (3-4 ulcers); and 3, severe (44 ulcers). Hyperplasia scoring was as follows: 0, normal; 1, crypts up to twice the normal thickness of normal epithelium; 2, crypts 42 times normal thickness, hyperchromatic epithelium; reduced goblet cells, scattered arborization; and 3, crypts 44 times normal thickness, marked hyperchromasia, few to no goblet cells, high mitotic index, frequent arborization. Disease area scoring was as follows: 0, 0-5% involvement; 1, 5-30%; 2, 30-70%; and 3, 470%. Total score is the sum of individual scores.
Cytokine levels. Frozen colon samples were homogenized in ice-cold phosphate-buffered saline containing 1% NP-40 and complete protease inhibitor cocktail (Roche, Basel, Switzerland). Cytokines and chemokines in samples were directly measured by Luminex (Bio-Rad, Hercules, CA) or ELISA (R&D Systems, Minneapolis, MN).
LP cell isolation. LP cells were isolated using a modification of a previously described protocol. 43 Briefly, colon segments were twice vigorously shaken in medium with 1 mM EDTA (Sigma-Aldrich, St Louis, MO) for 20 min at 37 1C, and suspended cells collected and filtered through a cell strainer. Tissue was further minced and incubated at 37 1C for 1 h in medium with 1 mM collagenase type IV (Sigma-Aldrich) and 40 U ml À 1 DNase I (Roche) with agitation. Cells were filtered, washed, and isolated over a Percoll step gradient (GE Healthcare, Pittsburgh, PA).
Bone marrow chimeras. Chimeras were produced as previously described. 44 Briefly, B5 Â 10 6 donor bone marrow cells were transplanted into lethally irradiated C57BL/6J recipients. Reconstitution was verified after 4 weeks by staining peripheral blood for the transplanted cells. Colitis was induced at 8 weeks.
Intestinal permeability. Epithelial barrier permeability was assessed using FITC-labeled dextran as described previously. 21 Briefly, mice were gavaged with FITC-dextran (Sigma-Aldrich, 1 g kg À 1 ) on day 7. After 6 h, blood was collected and the plasma FITC-dextran quantified by fluorescence spectrophotometry.
Epithelial cell proliferation. Proliferating intestinal epithelial cells were quantified as described previously. 45 Briefly, 5-bromodeoxyuridine (20 mg kg À 1 ) was administered intraperitoneally to mice with colitis (day 7) or untreated mice. After 2 h, colons were removed and cells incorporating 5-bromodeoxyuridine quantified by immunohistochemistry. The average number of 5-bromodeoxyuridine-positive epithelial cells per intact and well-oriented crypt was determined (minimum of 50 crypts assessed per mouse).
Cytokine PCR. Total RNA was isolated from sorted LPMfs using the RNeasy mini kit (Qiagen, Venlo, The Netherlands), and complementary DNA synthesized using superscript III and oligo (dT) primers (Invitrogen, Carlsbad, CA). Expression levels were normalized to HPRT (DCt) and compared with littermate controls using the DDCt method. 46 
